OncologyOnline.net

Oncology Xagena

Search results for "Everolimus"

Breast cancer patients with HER2-positive tumors who don't respond to Herceptin ( Trastuzumab ) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K inhibiting agents, ...


Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...


Treatment with Everolimus ( Certican ) prolongs progression-free survival relative to placebo in patients with metastatic kidney cancer ( renal cell carcinoma ) who have experienced treatment failur ...


New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus ( RAD001 ) significantly delays cancer progression in patients with m ...


Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. Resear ...


Results from CheckMate -025, a phase 3 study comparing Nivolumab ( Opdivo ) to Everolimus ( Afinitor ) in advanced renal cell carcinoma ( RCC ) after prior anti-angiogenic treatment, showed a signific ...


Neuroendocrine tumors ( NETs ) are a heterogeneous class of neoplasms with increasing incidence worldwide. Tumor behavior and patient survival largely depend upon a number of different factors such ...


A phase II trial of Everolimus plus Octreotide LAR as first-line treatment for patients with previously untreated, well-differentiated gastroenteropancreatic NETs and NETs of lung origin, both functio ...